BRAF V600E mutation results in an elevation in BRAF kinase activity, spanning from 130 to 700 times that of the wild-type, leading to prolonged aberrant activation of the Mitogen-activated Protein Kinase (MAPK) pathway and driving the initiation and progression of cancer [27]. The gene discussed is WNK2; the disease is cancer.